KR20030066813A - Ｄ-아미노산 산화효소와 ｄ-아스파르테이트 산화효소길항제를 이용한 ｃｎｓ 질환의 치료 - Google Patents
Ｄ-아미노산 산화효소와 ｄ-아스파르테이트 산화효소길항제를 이용한 ｃｎｓ 질환의 치료 Download PDFInfo
- Publication number
- KR20030066813A KR20030066813A KR10-2003-7009412A KR20037009412A KR20030066813A KR 20030066813 A KR20030066813 A KR 20030066813A KR 20037009412 A KR20037009412 A KR 20037009412A KR 20030066813 A KR20030066813 A KR 20030066813A
- Authority
- KR
- South Korea
- Prior art keywords
- dao
- alkyl
- ring
- compound
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26188301P | 2001-01-16 | 2001-01-16 | |
| US60/261,883 | 2001-01-16 | ||
| US30544501P | 2001-07-13 | 2001-07-13 | |
| US60/305,445 | 2001-07-13 | ||
| US34521101P | 2001-10-22 | 2001-10-22 | |
| US60/345,211 | 2001-10-22 | ||
| US33388101P | 2001-11-19 | 2001-11-19 | |
| US60/333,881 | 2001-11-19 | ||
| PCT/IB2002/001262 WO2002066672A2 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030066813A true KR20030066813A (ko) | 2003-08-09 |
Family
ID=27500728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7009412A Ceased KR20030066813A (ko) | 2001-01-16 | 2002-01-15 | Ｄ-아미노산 산화효소와 ｄ-아스파르테이트 산화효소길항제를 이용한 ｃｎｓ 질환의 치료 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1412515A2 (https=) |
| JP (1) | JP2004537275A (https=) |
| KR (1) | KR20030066813A (https=) |
| CN (1) | CN1568370A (https=) |
| AU (1) | AU2002247939B2 (https=) |
| BR (1) | BR0206495A (https=) |
| CA (1) | CA2433866A1 (https=) |
| EA (1) | EA006654B1 (https=) |
| IL (1) | IL156865A0 (https=) |
| MX (1) | MXPA03006321A (https=) |
| WO (1) | WO2002066672A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60228954D1 (en) | 2001-05-03 | 2008-10-30 | Galileo Lab Inc | Pyruvatderivate |
| WO2003070743A1 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| AU2002339696A1 (en) * | 2001-12-03 | 2003-06-17 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| US20060234221A1 (en) * | 2001-12-12 | 2006-10-19 | Genset S.A. | Biallelic markers of d-amino acid oxidase and uses thereof |
| GB0223424D0 (en) * | 2002-10-09 | 2002-11-13 | Imp College Innovations Ltd | Disease-associated gene |
| JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| JP5367377B2 (ja) * | 2006-01-09 | 2013-12-11 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患治療のためのランチオニン関連化合物 |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| GB2456390A (en) * | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| CN102292094B (zh) | 2009-01-20 | 2013-08-14 | 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 | 增强神经药方疗效的山梨酸与苯甲酸及其衍生物 |
| JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤 |
| WO2012135119A1 (en) * | 2011-03-25 | 2012-10-04 | Genomind, Llc | Biomarker-based detection and treatment of neurodegenerative depression |
| AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| RU2765625C2 (ru) | 2016-06-13 | 2022-02-01 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| CN108504752B (zh) * | 2018-06-26 | 2021-05-11 | 华中农业大学 | 一种与母猪繁殖性状关联的分子标记及应用 |
| CN111909907B (zh) * | 2020-07-08 | 2022-05-24 | 浙江工业大学 | 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| EP1165836A2 (en) * | 1999-03-30 | 2002-01-02 | Genset | Schizophrenia associated genes, proteins and biallelic markers |
| WO2001009118A2 (en) * | 1999-07-29 | 2001-02-08 | Patrick T Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
-
2002
- 2002-01-15 EP EP02717019A patent/EP1412515A2/en not_active Withdrawn
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Ceased
- 2002-01-15 CA CA002433866A patent/CA2433866A1/en not_active Abandoned
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002247939B9 (en) | 2002-09-04 |
| JP2004537275A (ja) | 2004-12-16 |
| EA200300807A1 (ru) | 2004-08-26 |
| CN1568370A (zh) | 2005-01-19 |
| EP1412515A2 (en) | 2004-04-28 |
| BR0206495A (pt) | 2006-01-24 |
| WO2002066672A2 (en) | 2002-08-29 |
| IL156865A0 (en) | 2004-02-08 |
| WO2002066672A3 (en) | 2004-02-26 |
| MXPA03006321A (es) | 2003-10-06 |
| CA2433866A1 (en) | 2002-08-29 |
| EA006654B1 (ru) | 2006-02-24 |
| AU2002247939B2 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002247939B2 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| AU2002247939A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| WO2003047558A2 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors | |
| Fisel et al. | Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy | |
| US20230348981A1 (en) | Methods and compositions for inhibiting and treating neurological conditions | |
| Willemse et al. | UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target | |
| Hirano et al. | Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? | |
| Huppke et al. | Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia | |
| Hebb et al. | Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington′ s disease transgenic mice prior to the onset of motor symptoms | |
| Chen et al. | The melanoma‐linked “redhead” MC1R influences dopaminergic neuron survival | |
| JP4585611B2 (ja) | 糖鎖関連遺伝子、およびその利用 | |
| US20080146540A1 (en) | Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association | |
| CA2704648A1 (en) | Methods and compositions for measuring wnt activation and for treating wnt-related cancers | |
| JP2002338502A (ja) | 脊柱筋萎縮症の治療 | |
| JP2011511845A (ja) | アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物 | |
| WO2007056388A2 (en) | Compositions and methods for modulating poly (adp-ribose) polymerase activity | |
| JP5980790B2 (ja) | バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン | |
| WO2014179303A1 (en) | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease | |
| Ruggiero et al. | Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake | |
| Patel et al. | Role of transporters and enzymes in metabolism and distribution of 4-chlorokynurenine (AV-101) | |
| MX2007015225A (es) | Chaperonas farmacologicas para el tratamiento de obesidad. | |
| Tarazi et al. | Brain dopamine D4 receptors: basic and clinical status | |
| Ennis et al. | Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter | |
| JP2006519189A (ja) | 白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用 | |
| CN101896815A (zh) | 肠疾病中的新的治疗靶标 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20030715 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050905 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060825 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070525 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20071120 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20070525 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20060825 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |